Patent classifications
A61M1/3496
Device for the selective removal of molecules from tissues or fluids
An implantable device is for the selective removal of molecules from tissues or fluids so as to allow the selective removal of a particular molecule of interest (target molecule) from any type of fluid solution or tissue, including biological tissues or fluids. The device operates through the complementary action of specific-binding molecules (antibodies) directed against the target molecule inside the device. The device includes a nanoperforated membrane having pores larger than the target molecule but smaller than the antibodies, such that the fluid can be removed through a second catheter with a lower concentration of target molecules.
MICROSCALE PLASMA SEPARATOR
The invention is directed to methods and devices for efficient separation of plasma irons whole blood which are suitable for point of care use in resource poor environments, in some embodiments, elements of such devices comprise (a) a sample collection receptacle (SCR) with at least one port, the sample collection receptacle capable of holding a predetermined volume of a sample of undiluted whole blood drawn through a port; (b) a filter chamber having an inlet and an outlet, and containing at least one filter capable of separating plasma from blood cells as sample passes from an inlet side to an outlet side of the at least one filter whenever the filter chamber is placed in Quid communication with a port of the sample collection receptacle; and (c) a manually driven pump operationally associated with the SCR and filter chamber for (i) drawing a predetermined volume of sample into ore SCR by a first user action and (ii) driving the predetermined volume at a substantially constant linear flow under a pressure not exceeding 2 psi from the SCR through the filter chamber and the outlet of the filter chamber by a second user action.
BLOOD FILTER AND METHOD OF MANUFACTURING THE SAME
Disclosed are a blood filter which exhibits excellent leukocyte elimination performance as well as significantly improved blood throughput per unit time and erythrocyte recovery rate and a method of manufacturing the same. The blood filter of the present invention includes a pre-treatment filter which is a laminate of first non-woven fabrics having a mean fiber diameter of 5 to 30 μm and a mean pore size of 10 to 30 μm, and a main filter which is a laminate of second non-woven fabrics having a mean fiber diameter of 1 to 5 μm, a mean pore size of 5 to 10 μm and a mean pore size distribution rate of 30% or more. A filling density of the pre-treatment filter and a filling density of the main filter, with respect to a target blood throughput of the blood filter, are 0.1 g/100 ml to 1 g/100 ml and 1 g/100 ml to 3 g/100 ml, respectively.
System and methods incorporating replacement fluid maximization
A processing system includes a processor including a separator, a set configured to cooperate with the separator to separate whole blood into plasma and other components, the set including an inlet line attachable to a patient to receive whole blood and an return line attachable to a patient to return processed fluid, and a source of replacement fluid connected to the disposable set, the processor configured to combine the other components with replacement fluid to define the processed fluid. The processor includes a controller and an input device coupled to the controller, the controller configured to receive an input via the input device, the input representing a volume of replacement fluid, and to control the processor to separate whole blood passing through the set and to combine the other components with the replacement fluid according to the input until the source of replacement fluid is empty.
SYSTEMS AND METHODS FOR OPTIMIZATION OF PLASMA COLLECTION VOLUMES
A method of collecting plasma includes receiving donor parameters at a controller of a plasma collection device electronically from a donor management system. The method includes storing a target volume for raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for raw plasma based on the total donor blood volume. The method includes setting the target volume for raw plasma and controlling the plasma collection device to operate draw and return phases to withdraw whole blood from a donor and separate the whole blood into the plasma product and a second blood component comprising red blood cells and to return the second blood component to the donor. The controller operates the draw and return phases until a volume of raw plasma in the collection container equals the target volume of raw plasma.
Systems and methods for determining free plasma hemoglobin
A system is provided for separating a plasma-containing fluid into separated plasma and a concentrated fluid. The system cooperates with a fluid flow circuit including a fluid separation chamber and a plasma outlet line associated therewith for removing separated plasma from the fluid separation chamber. The system includes an optical sensor assembly to monitor the contents of the plasma outlet line and produce an output indicative of the concentration of free plasma hemoglobin in the plasma outlet line. A controller of the system calculates the amount of free plasma hemoglobin in at least a portion of the concentrated fluid based at least in part on the output of the optical sensor assembly. The controller may periodically calibrate the optical sensor assembly by determining an instrument-specific correlation between optic output and free hemoglobin concentration and comparing it to experimentally determined data to ensure continued reliability of the optical sensor assembly.
SYSTEMS AND METHODS FOR PRIMING A FLUID CIRCUIT
Methods and systems for priming a disposable fluid circuit for the processing of a biological fluid are disclosed. The methods and systems allow for variable and configurable priming of the flow path(s) leading to one or more biological fluid source containers.
Methods for Treatment of Refractory Generalized Myasthenia Gravis
The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.
Dual Reservoir Implantable Access Port
An implantable access port for use in transferring fluid transdermally between an external fluid storage or dispensing device and a site within a patient is disclosed. The access port includes a body, at least two reservoirs defined within the access port body, and at least one septum secured to the body and enclosing the reservoirs within the body. The access port also includes reservoir outlets defined within the reservoirs. The access port also has body conduits defined within the body and in fluid communication with the reservoir outlets and external openings defined in the exterior of the body. An implantable access port and system for use in apheresis is also provided that includes an implantable access port, at least one needle, and a catheter that is fluidly connected to the access port.
Dialysis systems and related methods
A dialysis machine that includes a valve member having a deformable area configured to deform outwardly away when pressurized fluid is introduced into the valve member. The valve member is configured so that, when a dialysis fluid cassette is disposed in a cassette compartment of the dialysis machine and pressurized fluid is introduced into the valve member, the deformable area obstructs a fluid channel of the dialysis fluid cassette to control dialysis fluid flow therethrough.